Executive Summary
As an economic and financial analyst, reviewing the Unaudited Third Quarter 2026 Financial Statements of Juli Plc reveals a challenging operational environment characterized by significant top-line contraction, persistent margin pressures, and heavy reliance on structured debt and related-party financing. Despite navigating a high-cost operating landscape marked by soaring energy and professional overheads, the company faces structural hurdles that underscore the need for strategic recapitalization and aggressive cost rationalization.
1. Financial Performance & Revenue Dynamics
Juli Plc’s income statement for the period ended September 30, 2026, reflects a pronounced slowdown in commercial activity compared to the preceding year.
Turnover & Revenue Streams:
For the 9-month period ended September 30, 2026, revenue stood at N198.50 million ($N198,496,530.99$), down sharply from N383.11 million ($N383,114,046.09$) reported in the corresponding 9-month period of 2025.
The third-quarter (3-month) turnover similarly contracted to N51.64 million from N113.87 million in Q3 2025.
Core Drivers: The pharmaceutical division remains the primary revenue anchor, generating N46.77 million in Q3 2026 (compared to N105.50 million in Q3 2025), alongside modest contributions from household consumer goods (N4.87 million).
Cost of Sales & Gross Margins:
Cost of sales for the 9-month period scaled down proportionally to N134.28 million (vs. N254.71 million in 2025), leaving a Gross Profit of N64.21 million for the year-to-date.
However, high operational outlays pushed the company into negative gross margins and operating losses on a quarterly basis, reflecting acute inflationary pressures on inventory procurement and cost-of-goods-sold pass-through limitations.
2. Cost Structure & Administrative Overhead
Operating expenditures continue to exert severe pressure on Juli Plc’s bottom line. Key cost centers for the 9-month period include:
Energy & Utilities: Generator running expenses, including fuel and lubricants, accounted for a substantial cash outflow at N25.63 million for the 9 months, illustrating the crippling cost of independent power generation in the Nigerian operating climate.
Professional & Administrative Fees: Other professional fees stood at N20.09 million for the year-to-date, alongside audit fees of N3.50 million and significant license/registration subscriptions (N3.75 million).
Personnel Costs: Salaries and wages for the 9-month period amounted to N23.16 million, reflecting a lean workforce configuration.
3. Balance Sheet & Solvency Analysis
The statement of financial position as of September 30, 2026, highlights a tight liquidity position and reliance on debt obligations:
Asset Base: Total assets contracted to N138.62 million (down from N218.04 million at year-end 2025). This was driven by reductions in inventories (N25.02 million) and lower cash and cash equivalents (N5.54 million gross / N4.34 million net cash equivalent).
Liabilities & Debt Profile:
Term Loans: Non-current liabilities feature a restructured WEMA Bank Plc term loan standing at N114.06 million (Note 13).
Trade & Other Payables: Current liabilities expanded to N186.61 million, driven by trade payables and accruals (N41.68 million) and a substantial tax payable portfolio (N30.87 million).
Shareholders’ Equity: The company maintains a negative equity position of (N47.99 million), weighed down by accumulated retained losses of (N885.23 million), despite a paid-up share capital of N274.99 million (and share premium of N524.99 million).
4. Shareholding Structure & Corporate Governance
According to the board disclosures, Juli Plc’s ownership structure remains tightly held by major strategic investors:
Major Shareholders (>5%):
TBT Nigeria Limited: 28.58% (16,952,442 units / direct & indirect tracking)
Midas Investment & Property Limited: 27.57% (16,661,563 units)
Mrs. Julia Omoshalewa Adelusi Adeluyi: 10.60% (58,331,875 shares)
Prince Julius Adelusi-Adeluyi, OFR, mni: 10.40% (57,321,746 shares)
Compliance: The company affirms adherence to Rule 17.15 on the Disclosure of Dealings in Issuers’ Shares, confirming no insider defaults during the period under review.
5. Analyst Recommendations & Investor Outlook
Immediate Focus on Top-Line Revival: Management must urgently stabilize distribution networks and expand retail pharmacy volumes to reverse the 48% year-on-year revenue decline.
Energy & Cost Optimization: Mitigating high reliance on diesel-driven generator expenses through alternative energy adoption (such as commercial solar integration) is critical to preserving working capital.
Capital Restructuring: Given the negative retained earnings and stretched debt-to-equity metrics, institutional investors should monitor potential equity restructuring or debt-to-equity swaps with major stakeholders (such as Midas and TBT) to clean up the balance sheet and restore positive net asset value.
Investor Takeaway: Juli Plc remains a turnaround play. While heritage brand equity and strong insider backing provide foundational resilience, near-term viability hinges on aggressive cost containment, debt restructuring, and a rebound in core pharmaceutical sales.
